Form 4: Director Acquires CSBR Stock Options

Champions Oncology Director Philip P. Breitfeld acquired 13,790 options to purchase common stock at an exercise price of $6.80, vesting over 12 months.

Summary

• Philip P. Breitfeld, a Director of CHAMPIONS ONCOLOGY, INC. (CSBR), reported the acquisition of derivative securities.
• The transaction involved an option to purchase 13,790 shares of Common Stock.
• The exercise price for these options is $6.80 per share.
• The options were granted on November 5, 2025, which is also the earliest transaction date.
• The options vest over a twelve-month period, with specific vesting dates on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.
• The options are exercisable over a ten-year period, with an expiration date of November 5, 2035.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director generally indicates alignment of interests with shareholders, as the director's future compensation is tied to the company's stock performance. This is a routine compensation event, slightly positive for governance.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• This grant represents a form of long-term incentive compensation for the director, potentially encouraging sustained commitment to the company's success.

Future Outlook

The options granted to Director Philip P. Breitfeld will vest over a twelve-month period, with the final tranche vesting in August 2026, and remain exercisable until November 2035, indicating a long-term incentive structure tied to future stock performance.

Stakeholder Impact

• Shareholders: The grant of options to a director can enhance alignment between management and shareholder interests, as the director's financial incentives are tied to the company's stock price appreciation.

Next Steps

• The options will vest in tranches on February 5, 2026, May 5, 2026, and August 5, 2026.
• The director may choose to exercise the vested options at any point before their expiration on November 5, 2035.

Key Dates

Keywords

CHAMPIONS ONCOLOGY, CSBR, stock options, insider transaction, Form 4, director compensation, equity grant